Key Details
Annual ROE
-154.69%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Mar 18, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with AUGX included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Similar stocks
SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure.
If you're considering an investment in penny stocks, you should consider looking into those in markets with a lot of room for innovation.
NEW YORK , Sept. 6, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
Augmedix, Inc. (AUGX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago.
SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024.
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Augmedix , Inc . ( Nasdaq : AUGX ) , relating to its proposed merger with Commure, Inc. Under the terms of the agreement, Augmedix stock will be converted into the right to receive $2.35 in cash per share.
Amid a sea of red in today's stock market, AI medical documentation and data solutions company Augmedix (NASDAQ: AUGX ) is certainly among the standout winners. Shares of AUGX stock have skyrocketed 150% in afternoon trading on a rather substantial announcement.
MILWAUKEE , July 19, 2024 /PRNewswire/ -- Ademi LLP is investigating Augmedix (Nasdaq: AUGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Commure. Click here to learn how to join our investigation https://www.ademilaw.com/case/augmedix-inc or call Guri Ademi toll-free at 866-264-3995.
Combination to Strengthen Ability to Deliver Frontier Ambient AI Solutions; Augmedix Stockholders to Receive $2.35 Per Share in All-Cash Acquisition by Commure Combination to Strengthen Ability to Deliver Frontier Ambient AI Solutions; Augmedix Stockholders to Receive $2.35 Per Share in All-Cash Acquisition by Commure
Augmedix stock is declining on Tuesday following the release of its Q1 2024 earnings report, with disappointing news coming from its outlook update for investors.
FAQ
- What is the primary business of Augmedix?
- What is the ticker symbol for Augmedix?
- Does Augmedix pay dividends?
- What sector is Augmedix in?
- What industry is Augmedix in?
- What country is Augmedix based in?
- When did Augmedix go public?
- Is Augmedix in the S&P 500?
- Is Augmedix in the NASDAQ 100?
- Is Augmedix in the Dow Jones?
- When was Augmedix's last earnings report?
- When does Augmedix report earnings?
- Should I buy Augmedix stock now?